Skip to Main Content
Contribute Try STAT+ Today

The Massachusetts Institute of Technology has ended negotiations over a new contract with the major journal publisher Elsevier, making it the latest high-profile academic institution to walk away from Elsevier amid an escalating fight that could shape the way that academic research gets read and paid for.

The decision, announced on Thursday, is the result of an ongoing dispute over open-access research, which is made freely available to the public online. MIT’s move follows the giant University of California system, which last year decided not to renew its subscriptions to Elsevier-published journals after months of negotiations, and the SUNY system in New York, which announced this spring that it would not renew its bundled journal subscription deal with Elsevier and instead only pay for a core list of a few hundred journals. A consortium representing universities and research institutes in Germany has also walked away from the negotiating table with Elsevier.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.